Altevax
Develops melanin-adjuvant peptide immunotherapies for cancer patients, initially targeting glioblastoma
Highlights
- New on EvolcAdded 2026-11-14
About Altevax
Altevax is developing an immunotherapy that combines melanin as an adjuvant with peptides specific to a targeted disease, aiming to trigger an antigen-specific T-cell response. Its initial clinical application is glioblastoma.
The company is based in Paris and was founded in 2016. It holds patents and is the exclusive worldwide licensee for the melanin technology patent.
Product: A melanin-adjuvant peptide immunotherapy platform, with a clinical program targeting glioblastoma.
Jobs at Altevax
More biotech & pharma companies
Ambiotis
Contract research on inflammation resolution and lipid analytics for pharma, dermo-cosmetic and nutraceutical companiesNew on EvolcAmgen
Biotechnology company developing and manufacturing therapies for serious diseases, operating in FranceAmoneta Diagnostics
Blood-based diagnostic assays and biomarker tools for healthcare professionals and neurological researchersNew on EvolcAmpleia
Venture builder creating biotech companies from research teams developing treatments for rare diseasesYoung companyNew on EvolcAnalysis Expertise
Forensic toxicology and genetic testing for courts and law enforcement agenciesYoung companyAntabio
Clinical-stage biopharma developing antibiotics for multidrug-resistant hospital infections in wards and ICUsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
Content management
- WixHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Monitoring
- SentryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.